Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risk-adapted therapy for primary AML in adults up to 70
NCT04687098Phase 2Completed
- Start
- Feb 2012
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of idarubicin, cytarabine in acute myeloid leukemia (AML). Started Feb 2012; status: completed.
02
Drugs
idarubicincytarabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04687098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04687098.